CRIS Current Research Information System

FUSAROLI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.118
EU - Europa 1.182
NA - Nord America 1.073
SA - Sud America 142
AF - Africa 78
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.615
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.042
CN - Cina 830
SG - Singapore 632
IT - Italia 560
HK - Hong Kong 171
KR - Corea 163
VN - Vietnam 122
DE - Germania 114
BR - Brasile 112
IN - India 99
NL - Olanda 98
SE - Svezia 81
GB - Regno Unito 54
RU - Federazione Russa 47
FI - Finlandia 40
CI - Costa d'Avorio 36
IE - Irlanda 34
JP - Giappone 32
ID - Indonesia 28
AT - Austria 26
BG - Bulgaria 24
CA - Canada 24
FR - Francia 24
CH - Svizzera 22
TG - Togo 21
AR - Argentina 19
ES - Italia 17
AU - Australia 13
NZ - Nuova Zelanda 8
PL - Polonia 7
PT - Portogallo 7
ZA - Sudafrica 7
TR - Turchia 6
BD - Bangladesh 5
GR - Grecia 5
MX - Messico 5
BE - Belgio 4
IQ - Iraq 4
LT - Lituania 4
BA - Bosnia-Erzegovina 3
CL - Cile 3
CO - Colombia 3
EG - Egitto 3
JO - Giordania 3
MY - Malesia 3
NG - Nigeria 3
PK - Pakistan 3
RS - Serbia 3
SC - Seychelles 3
TH - Thailandia 3
UA - Ucraina 3
EC - Ecuador 2
KE - Kenya 2
KZ - Kazakistan 2
MA - Marocco 2
PE - Perù 2
PH - Filippine 2
SA - Arabia Saudita 2
SI - Slovenia 2
AE - Emirati Arabi Uniti 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DM - Dominica 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
NP - Nepal 1
TN - Tunisia 1
UZ - Uzbekistan 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
Totale 4.615
Salva come PNG Salva come JPEG
Città #
Singapore 454
Hefei 399
Ashburn 202
Bologna 194
Hong Kong 168
Seoul 162
Santa Clara 85
Chandler 74
Beijing 60
Boardman 50
Ho Chi Minh City 43
Milan 43
Los Angeles 40
Dallas 37
Abidjan 36
Bengaluru 36
Dublin 33
Princeton 28
The Dalles 28
Tokyo 28
Hanoi 27
Helsinki 24
Jakarta 24
Redmond 24
Sofia 24
Southend 24
Lomé 21
Redondo Beach 21
Bern 19
Buffalo 17
Modena 16
Rome 16
Shanghai 16
Vienna 16
Munich 15
New York 13
Fairfield 12
Tongling 12
Frankfurt am Main 11
Nuremberg 11
São Paulo 11
Cesena 10
Toronto 10
Turin 10
Chicago 9
Florence 9
Lappeenranta 9
San Diego 9
Indianapolis 8
London 8
Monselice 8
Biên Hòa 7
Guangzhou 7
Phoenix 7
Atlanta 6
Auckland 6
Berlin 6
Cambridge 6
Embrun 6
Hyderabad 6
Jinan 6
Lizzano 6
Mercato Saraceno 6
Palermo 6
Seattle 6
Shenzhen 6
Suzhou 6
Turku 6
Verona 6
Visakhapatnam 6
Xi'an 6
Amsterdam 5
Barcelona 5
Council Bluffs 5
Falkenstein 5
Haiphong 5
Hangzhou 5
Houston 5
Mülheim 5
Perth 5
Pune 5
Stockholm 5
Taizhou 5
Ann Arbor 4
Bexley 4
Boydton 4
Brasília 4
Brooklyn 4
Brussels 4
Bühl 4
Casalecchio di Reno 4
Casalgrande 4
Chengdu 4
Des Moines 4
Melbourne 4
Mexico City 4
Padova 4
Paris 4
Reggio Emilia 4
San Francisco 4
Totale 2.915
Salva come PNG Salva come JPEG
Nome #
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions 261
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System 184
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 181
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct 173
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System 157
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study 143
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies 142
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS 141
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System 141
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People 138
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 133
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry 126
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 124
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase 119
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement 113
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors 112
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System 110
Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency 108
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study 105
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration 104
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 102
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System 101
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database 99
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System 99
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 95
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 94
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System 93
Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list 88
Post-marketing safety profile of cannabis products: Signals from the FDA adverse event reporting system 86
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis 85
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians 85
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline 83
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal 77
What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System 73
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance 72
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System 67
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system 62
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System 57
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System 55
Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance” 53
Environmental sustainability-an essential component of rational use of medicines 51
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database 50
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach 47
Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports A Note of Caution 46
The evolving role of disproportionality analysis in pharmacovigilance 40
Interpretation of Pharmacovigilance Disproportionality Analyses 31
Real-world evidence and pharmacovigilance: workshop of the Italian Epidemiological Association and of the Italian Society of Pharmacology 28
Transparency and robustness of safety signals 14
Totale 4.748
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.929
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.929
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202136 0 0 0 0 0 0 1 8 11 8 1 7
2021/2022256 1 0 7 10 10 10 36 47 20 21 58 36
2022/2023478 36 19 31 32 48 38 45 48 81 14 54 32
2023/2024420 36 41 41 56 43 60 22 39 15 30 30 7
2024/20251.651 93 139 165 104 129 66 109 129 65 119 175 358
2025/20261.907 406 508 340 301 330 22 0 0 0 0 0 0
Totale 4.748